Publicoffering — Trading Ideas on TradingView

PLU Power Price crushed by dilution announcement LONG On the 15 minute chart, PLUG got a deserving bad haircut today on the dilution announcement. Buying shares in a chas burning enterprise is risky business. However, the prospects of a rescue with a federal grant from the Green Left initiative can come any time. Shares are on sale. So are OTM call options expiring after the recovery if there is one. Price is showing a glimmer of a bounce with upgoing MACD lines and the fast RSI line rising and crossing over the slower one and heading to the 50 level. I will take a long trade when price gets through the Ichimoku cloud at 3.15 with a stop just below the cloud. I may add to it when price gets over the upper VWAP band situated at 3.5 which is confluent with the 0.5 Fib retracement price value. As a penny stock, all can afford stock or options. As to the options, the monthly in two days if only a prospect for those trading options.in a day-trade or nearly day trade fashion, I will look at the February 16 expiring options with a strike of $ 4.00 to $ 5.00 and take a bunch of them allowing for secondary targets and taking partial profits.

SEND ABOVE 1USDT TO THIS ADDRESS, WE'VE GOT A TARGET🎯Meet Julia, She's been trying hard to get into college, and she finally got in, sad part is her family does NOT have enough to pay for her college tuitions. There's only so far I can go in helping her as an individual... I decided to ask the Public to help in her aid! Here's the USDT ADDRESS: TRC20; TL2QbgdAERJRc6KXCsT5viKCG72p9PsPNq Make it count!🎯

Surgalign Holdings Inc 🧙Surgalign Holdings Inc is a medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company continues to invest in clinically validated innovation to deliver better surgical outcomes and improve patient's lives. It markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. The U.S. market accounts for the vast majority of revenue. It has commercial and design centers in San Diego, California, and Wurmlingen, Germany. If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!

DSS Technical Analysis 🧙Document Security Systems Inc operates in the security and commercial printing, packaging and plastic ID markets. The company develops, markets, manufactures and sells paper and plastic products designed to protect valuable information from unauthorized scanning, copying, and digital imaging. It is organized into the operating segments of Packaging and Printing; Plastics; Digital; Technology management; and Corporate. The Packaging and Printing, and Plastics segments, which are the key revenue-generating segments, are engaged in the printing and production of paper, cardboard and plastic documents with a wide range of features designed for the protection of documents against unauthorized duplication and altering. Document Security Systems, Inc. a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, today announced the pricing of an upsized underwritten public offering with gross proceeds to the Company expected to be approximately $34.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The public offering equates to 12,319,346 shares of the Company’s common stock at a price of $2.80 per share. The Company intends to use the net proceeds from this offering, together with their existing cash, to fund the development and growth of new business lines, acquisition opportunities, and general corporate and working capital needs. The Company has also granted the underwriters a 45-day option to purchase up to an additional 15% of shares of common stock offered in the public offering to cover over-allotments, if any, which would increase the total gross proceeds of the offering to approximately $39.7 million, if exercised in full. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!

Closing of an Upsized $20.7 Million Underwritten Public Offering InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering $NSPR today announced the pricing of an upsized underwritten public offering of securities for gross proceeds of $18 million (or $20.7 million if the underwriters exercise their option to purchase additional securities) prior to deducting underwriting discounts and estimated offering expenses payable by InspireMD. The offering is comprised of 29,032,258 Units, priced at a public offering price of $0.62 per Unit, with each Unit consisting of one share of Common Stock and one Series G Warrant to purchase one-half of one share of Common Stock, at an exercise price of $0.682 per share and expiring on the fifth anniversary of the date of issuance. finance.yahoo.com InspireMD Announces Closing of an Upsized $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option $NSPR today announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately $20.7 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by InspireMD. finance.yahoo.com

DSS - Great Buy Opportunity after Public Offering Price collapsed due to Public Offering Huge investment on the company (24M$) Previous earnings were positive, growing business 4$ is a GREAT price Multiweek / Multimonth depending on TP

SELLAS Announces Pricing of $15 Million Public Offering.SELLAS intends to use the net proceeds from the offering to commence a pivotal Phase 3 trial for its lead clinical candidate, galinpepimut-S (“GPS”), as a monotherapy in acute myeloid leukemia patients following second complete remission and to continue its Phase 1/2 basket type trial of GPS in combination with pembrolizumab, as well as for general corporate purposes and funding its working capital needs.